Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M

Lucid Diagnostics Inc.

Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).
Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.
Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lucid Diagnostics Inc. reported the first quarter ended March 31, 2026 results: revenue $1.3 million, net income $23.6 million, EPS $(0.17) per common share.

Period: the first quarter ended March 31, 2026
Revenue: $1.3 million
Net income: $23.6 million
EPS: $(0.17) per common share
Result: reported results

Exact text from the filing

(EX-99.1) --- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May

View on SEC.gov

Browse all earnings releases →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.